{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:20Z","timestamp":1791228680952,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40266-013-0129-1","type":"journal-article","created":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T09:03:16Z","timestamp":1383210196000},"page":"979-986","source":"Crossref","is-referenced-by-count":3,"title":["Management of Mantle Cell Lymphoma in the Elderly: Current and Potential Strategies"],"prefix":"10.1007","volume":"30","author":[{"given":"Marguerite","family":"Vignon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Dominique","family":"Venon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"key":"129_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcancer.2011.09.010","volume":"21","author":"KE Smedby","year":"2011","unstructured":"Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21:293\u20138.","journal-title":"Semin Cancer Biol"},{"key":"129_CR2","volume-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"AJ Swerdlow","year":"2008","unstructured":"Swerdlow AJ, Campo E, Harris ES, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: France IARC Press; 2008."},{"key":"129_CR3","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1182\/blood-2007-10-118794","volume":"111","author":"I Wlodarska","year":"2008","unstructured":"Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood. 2008;111:5683\u201390.","journal-title":"Blood"},{"key":"129_CR4","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","volume":"94","author":"A Mozos","year":"2009","unstructured":"Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555\u201362.","journal-title":"Haematologica"},{"key":"129_CR5","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/10428190802094245","volume":"49","author":"C Thieblemont","year":"2008","unstructured":"Thieblemont C, Rolland D, Baseggio L, et al. Comprehensive analysis of GST-\u03c0 expression in B-cell lymphomas: correlation with histological subtypes and survival. Leuk Lymphoma. 2008;49:1403\u20136.","journal-title":"Leuk Lymphoma"},{"key":"129_CR6","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","volume":"106","author":"K Fu","year":"2005","unstructured":"Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315\u201321.","journal-title":"Blood"},{"key":"129_CR7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","volume":"87","author":"JM Vose","year":"2012","unstructured":"Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2012;87:604\u20139.","journal-title":"Am J Hematol"},{"key":"129_CR8","first-page":"181","volume":"113","author":"SH Swerdlow","year":"1983","unstructured":"Swerdlow SH, Habeshaw JA, Murray LJ, et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol. 1983;113:181\u201397.","journal-title":"Am J Pathol"},{"key":"129_CR9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"129_CR10","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385\u20137.","journal-title":"Blood"},{"key":"129_CR11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511\u20138.","journal-title":"J Clin Oncol"},{"key":"129_CR12","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215\u201323.","journal-title":"Blood"},{"key":"129_CR13","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00259-010-1469-2","volume":"37","author":"C Bodet-Milin","year":"2010","unstructured":"Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS Group. Eur J Nucl Med Mol Imaging. 2010;37:1633\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"129_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.seminhematol.2011.03.010","volume":"48","author":"P Martin","year":"2011","unstructured":"Martin P, Leonard J. Is there a role for \u201cwatch and wait\u201d in patients with mantle cell lymphoma? Semin Hematol. 2011;48:189\u201393.","journal-title":"Semin Hematol"},{"key":"129_CR15","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307\u201316.","journal-title":"Cancer Res"},{"key":"129_CR16","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","volume":"119","author":"L Nygren","year":"2012","unstructured":"Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119:4215\u201323.","journal-title":"Blood"},{"key":"129_CR17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209\u201313.","journal-title":"J Clin Oncol"},{"key":"129_CR18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SFH, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705\u201311.","journal-title":"J Clin Oncol"},{"key":"129_CR19","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984\u201392.","journal-title":"J Clin Oncol"},{"key":"129_CR20","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064\u201371.","journal-title":"Blood"},{"key":"129_CR21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706\u201314.","journal-title":"J Natl Cancer Inst"},{"key":"129_CR22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520\u201331.","journal-title":"N Engl J Med"},{"key":"129_CR23","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013. doi: 10.1016\/S0140-6736(12)61763-2 .","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"129_CR24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 2002;16:587\u201393.","journal-title":"Leukemia"},{"key":"129_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","volume":"39","author":"JE Romaguera","year":"2000","unstructured":"Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000;39:77\u201385.","journal-title":"Leuk Lymphoma"},{"key":"129_CR26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase\u00a02 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood. 2013;121:48\u201353.","journal-title":"Blood"},{"key":"129_CR27","doi-asserted-by":"crossref","unstructured":"Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3\u00d7 CHOP and 3\u00d7 DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts). 2012;120:151.","DOI":"10.1182\/blood.V120.21.151.151"},{"key":"129_CR28","doi-asserted-by":"crossref","unstructured":"Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442\u20139.","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"129_CR29","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"129_CR30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdr035","volume":"23","author":"E Jantunen","year":"2012","unstructured":"Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65\u00a0years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23:166\u201371.","journal-title":"Ann Oncol"},{"key":"129_CR31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2010","unstructured":"Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase\u00a03, randomised controlled trial. Lancet. 2010;377:42\u201351.","journal-title":"Lancet"},{"key":"129_CR32","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Li H, Gordon L, Gascoyne RD, et al. Phase\u00a0II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90\u2013ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30:3119\u201326.","journal-title":"J Clin Oncol"},{"key":"129_CR33","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","volume":"27","author":"NS Andersen","year":"2009","unstructured":"Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27:4365\u201370.","journal-title":"J Clin Oncol"},{"key":"129_CR34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.seminhematol.2011.03.008","volume":"48","author":"HC Kluin-Nelemans","year":"2011","unstructured":"Kluin-Nelemans HC, Doorduijn JK. Treatment of elderly patients with mantle cell lymphoma. Semin Hematol. 2011;48:208\u201313.","journal-title":"Semin Hematol"},{"key":"129_CR35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349\u201360.","journal-title":"Nat Rev Cancer"},{"key":"129_CR36","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase\u00a0II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867\u201374.","journal-title":"J Clin Oncol"},{"key":"129_CR37","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","volume":"23","author":"R Houot","year":"2012","unstructured":"Houot R, Gouill SL, Uribe MO, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase\u00a0II trial from the GOELAMS. Ann Oncol. 2012;23:1555\u201361.","journal-title":"Ann Oncol"},{"key":"129_CR38","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807\u201312.","journal-title":"Blood"},{"key":"129_CR39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase\u00a03, non-inferiority study. Lancet Oncol. 2011;12:431\u201340.","journal-title":"Lancet Oncol"},{"key":"129_CR40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11864-006-0038-1","volume":"7","author":"TE Witzig","year":"2006","unstructured":"Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol. 2006;7:285\u201394.","journal-title":"Curr Treat Options Oncol"},{"key":"129_CR41","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, et al. Phase\u00a0III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822\u20139.","journal-title":"J Clin Oncol"},{"key":"129_CR42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase\u00a02 study. Lancet Oncol. 2011;12:361\u20138.","journal-title":"Lancet Oncol"},{"key":"129_CR43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","volume":"97","author":"C Renner","year":"2012","unstructured":"Renner C, Zinzani PL, Gressin R, et al. A multicenter phase\u00a0II trial (SAKK\u00a036\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012;97:1085\u201391.","journal-title":"Haematologica"},{"key":"129_CR44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/13543784.2012.640318","volume":"21","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012;21:15\u201322.","journal-title":"Expert Opin Investig Drugs"},{"key":"129_CR45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/IR:23:2-3:147","volume":"23","author":"WN Khan","year":"2001","unstructured":"Khan WN. Regulation of B\u00a0lymphocyte development and activation by Bruton\u2019s tyrosine kinase. Immunol Res. 2001;23:147\u201356.","journal-title":"Immunol Res"},{"key":"129_CR46","doi-asserted-by":"crossref","unstructured":"Wang M, Rule SA, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","DOI":"10.1056\/NEJMoa1306220"},{"key":"129_CR47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.beha.2012.04.005","volume":"25","author":"R Dawar","year":"2012","unstructured":"Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best Pract Res Clin Haematol. 2012;25:185\u201390.","journal-title":"Best Pract Res Clin Haematol"},{"key":"129_CR48","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","volume":"17","author":"G Damaj","year":"2003","unstructured":"Damaj G, Lefrere F, Delarue R, et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003;17:1914\u20135.","journal-title":"Leukemia"},{"key":"129_CR49","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","volume":"104","author":"H Kaufmann","year":"2004","unstructured":"Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma. Blood. 2004;104:2269\u201371.","journal-title":"Blood"},{"key":"129_CR50","doi-asserted-by":"crossref","unstructured":"Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688\u201395.","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"129_CR51","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase\u00a01\/2 clinical trial. Lancet Oncol. 2012;13:716\u201323.","journal-title":"Lancet Oncol"},{"key":"129_CR52","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","volume":"13","author":"ME Hamaker","year":"2012","unstructured":"Hamaker ME, Jonker JM, De Rooij SE, et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13:e437\u201344.","journal-title":"Lancet Oncol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-013-0129-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0129-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T04:57:14Z","timestamp":1596776234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-013-0129-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1007\/s40266-013-0129-1","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]}}}